Passage Bio has launched to develop treatments for diseases affecting the central nervous system, after raising almost $116m in a series A round backed by Lilly Asia Ventures.
Passage Bio, a US-based company developing treatments for neurological diseases, has received approximately $116m in a series A round that included Lilly Asia Ventures, an investment vehicle for pharmaceutical firm Eli Lilly.
The round was led by OrbiMed and included fellow healthcare investment firm Vivo Capital as well as venture capital firms Frazier Healthcare Partners, Versant Ventures and New Leaf Venture Partners.
Passage Bio is developing five drug candidates that are intended to treat diseases affecting the central nervous system…
